银屑病和银屑病关节炎研究与评估小组/风湿病学结局测量共识建议及研究议程:银屑病关节炎复合测量与治疗目标的使用
银屑病和银屑病关节炎研究与评估小组(GRAPPA)与风湿病学结局测量(OMERACT)联合召开共识会议,基于128名医护人员和139例患者的调查及系统文献综述,对银屑病关节炎复合测量和治疗目标进行投票。会议未就单一连续复合测量达成共识,但推荐几种复合测量可供使用;一致同意缓解为理想目标,极低疾病活动度(VLDA)或最小疾病活动度(MDA)为推荐治疗目标。
要点
- 未就单一连续复合测量达成共识,推荐几种复合测量供使用。
- 一致同意缓解为理想目标,VLDA或MDA为推荐治疗目标。
- 治疗目标应涵盖肌肉骨骼、皮肤及健康相关生活质量评估。
核心结论
- 未就疾病活动度的连续测量达成共识, interim推荐几种复合测量。
- 就VLDA/MDA作为治疗目标达成共识。
- 制定了广泛的研究议程,建议在 ongoing研究中收集所有PsA临床领域的数据。
研究设计与样本
- GRAPPA与OMERACT联合召开共识会议,26名风湿病学家、皮肤科医生和患者研究伙伴参与。
- 会前医护人员和患者完成结局测量调查,会议回顾复合测量和治疗目标的证据及调查结果。
- 会议包括全体报告、分组讨论和小组讨论,所有讨论测量的开发人员受邀参加,会后投票并在第二次调查中建立共识。
主要发现
- 分析了128名医护人员和139例患者的调查结果,并结合系统文献综述。
- 随机对照试验中最受欢迎的复合测量为PsA疾病活动度评分(40票)和GRAPPA复合指数(28票)。
- 临床实践中最受欢迎的复合测量为3个视觉模拟量表评分的平均值(45票)和PsA疾病活动度评分(26票)。
- 讨论后未就复合测量达成共识,但小组同意几种复合测量可供使用,未来研究应允许进一步验证和比较。
- 小组一致同意缓解应为理想目标,MDA/低疾病活动度为可行的替代目标;目标应包括肌肉骨骼疾病、皮肤疾病和健康相关生活质量的评估。
关键数值与推荐
- 推荐治疗目标为VLDA或MDA。
- 随机对照试验中最受欢迎的测量:PsA疾病活动度评分40票,GRAPPA复合指数28票。
- 临床实践中最受欢迎的测量:3个视觉模拟量表评分的平均值45票,PsA疾病活动度评分26票。
临床怎么用
- 小组推荐几种复合测量可供使用。
- 小组推荐治疗目标为VLDA或MDA。
- 治疗目标应包括肌肉骨骼疾病、皮肤疾病和健康相关生活质量的评估。
局限性
- 未就疾病活动度的连续测量达成共识。
- 小组同意未来研究应允许进一步验证和比较复合测量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: A meeting was convened by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and Outcome Measures in Rheumatology (OMERACT) to further the development of consensus among physicians and patients regarding composite disease activity measures and targets in psoriatic arthritis (PsA). METHODS: Prior to the meeting, physicians and patients completed surveys on outcome measures. A consensus meeting of 26 rheumatologists, dermatologists, and patient research partners reviewed evidence on composite measures and potential treatment targets plus results of the surveys. The meeting consisted of plenary presentations, breakout sessions, and group discussions. International experts including members of GRAPPA and OMERACT were invited to the meeting, including the developers of all of the measures discussed. After discussions, participants voted on proposals for use, and consensus was established in a second survey. RESULTS: Survey results from 128 health care professionals and 139 patients were analyzed alongside a systematic literature review summarizing evidence. A weighted vote was cast for composite measures. For randomized controlled trials, the most popular measures were the PsA disease activity score (40 votes) and the GRAPPA composite index (28 votes). For clinical practice, the most popular measures were an average of scores on 3 visual analog scales (45 votes) and the disease activity in PsA score (26 votes). After discussion, there was no consensus on a composite measure. The group agreed that several composite measures could be used and that future studies should allow further validation and comparison. The group unanimously agreed that remission should be the ideal target, with minimal disease activity (MDA)/low disease activity as a feasible alternative. The target should include assessment of musculoskeletal disease, skin disease, and health-related quality of life. The group recommended a treatment target of very low disease activity (VLDA) or MDA. CONCLUSION: Consensus was not reached on a continuous measure of disease activity. In the interim, the group recommended several composites. Consensus was reached on a treatment target of VLDA/MDA. An extensive research agenda was composed and recommends that data on all PsA clinical domains be collected in ongoing studies.
引用
- Coates LC, FitzGerald O, Merola JF, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. Arthritis Rheumatol. 2018. PMID: 29193765. doi:10.1002/art.40391
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。